Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2017, Vol.66 (1), p.S207-S207
Main Authors: Mahalingam, D, Peguero, J, Cen, P, Allgood, V, Shazer, R, Campos, L
Format: Article
Language:English
Subjects:
Gastroenterology and Hepatology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0168-8278
DOI:10.1016/S0168-8278(17)30711-0